Everpar Advisors LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Everpar Advisors LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,884 shares of the medical research company’s stock, valued at approximately $918,000.

A number of other hedge funds have also made changes to their positions in CRL. Meritage Group LP purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $173,174,000. Rhenman & Partners Asset Management AB acquired a new position in Charles River Laboratories International in the 3rd quarter worth $48,603,000. Montrusco Bolton Investments Inc. lifted its holdings in Charles River Laboratories International by 35.8% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 855,387 shares of the medical research company’s stock worth $164,058,000 after buying an additional 225,562 shares in the last quarter. Armistice Capital LLC acquired a new position in Charles River Laboratories International in the 3rd quarter worth $30,573,000. Finally, abrdn plc lifted its holdings in Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,932 shares of company stock worth $3,693,663. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird boosted their price objective on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Citigroup upped their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Stock Performance

CRL stock traded down $0.97 during midday trading on Wednesday, reaching $235.34. The company had a trading volume of 610,304 shares, compared to its average volume of 543,878. The firm has a market capitalization of $12.12 billion, a PE ratio of 25.66, a P/E/G ratio of 1.83 and a beta of 1.44. The stock has a 50 day moving average price of $251.61 and a 200 day moving average price of $225.17. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same quarter in the previous year, the firm posted $2.98 EPS. The business’s revenue for the quarter was down 7.9% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).